Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) recorded 1.32% gain during trading session on April 15th, 2019. The script traded as low as $14.30 and last traded at $14.57. 7.77 million shares changed exchanged hands during trading, an increase of 26.97% from the 30-day average session volume of 10.64M shares. The firm had previously closed at $14.38. The company has $1.08B outstanding shares, price-to-earnings-growth ratio of 0.84 and a beta of 1.33. The company has a RSI of 33.90, ATR of 0.43 and a volatility of 2.99% this week. TEVA has a 52 week low price of $14.27 and a 52 week high price of $25.96.
Investors have identified the tech company Teva Pharmaceutical Industries Limited as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 15.80B, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Teva Pharmaceutical Industries Limited (TEVA) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For TEVA, the company has in raw cash 1.78 billion on their books with 2.74 billion currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 0 total, with 5.96 billion as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.
TEVA were able to record 1.8 billion as free cash flow during the recently reported quarter of the year, this saw their quarterly net cash flow reduce by 819 million. In cash movements, the company had a total of 2.45 billion as operating cash flow.
Potential earnings growth for Teva Pharmaceutical Industries Limited (TEVA)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Teva Pharmaceutical Industries Limited recorded a total of 4.56 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -0.18% coming in sequential stages and their sales for the third quarter increasing by 0.01%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 2.69 billion trying to sell their products during the last quarter, with the result yielding a gross income of 1.87 billion. This allows shareholders to hold on to 1.08B with the revenue now reading -3180 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (0.58 cents a share).
Is the stock of TEVA attractive?
Having a look at the company’s valuation, the company is expected to record 2.52 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TEVA sounds very interesting.
In related news, EVP, North America Commercial O’Grady Brendan P. sold 1,179 shares of the company’s stock in a transaction that recorded on March 18th, 2019. The sale was performed at an average price of 16.63, for a total value of 19,601. As the sale deal closes, the EVP, Growth Markets Commercial O’Grady Brendan P. now sold 320 shares of the company’s stock, valued at 5,326. Also, Exec. VP, European Commercial Daniell Richard sold 1,297 shares of the company’s stock in a deal that was recorded on March 18th, 2019. The shares were sold at an average price of 16.64 per share, with a total market value of 0. Following this completion of acquisition, the Exec. VP Chief Legal Officer now holds 2,358 shares of the company’s stock, valued at 38,742. In the last 6 months, insiders have changed their ownership in shares of company stock by 2.70%.
3 out of 25 analysts covering the stock have rated it a Buy, while 18 have maintained a Hold recommendation on Teva Pharmaceutical Industries Limited stock. 0 analysts has assigned a Sell rating on the TEVA stock. The 12-month mean consensus price target for the company’s shares has been set at $20.20.